Open Access

Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma

Contributed equally
Journal of Hematology & Oncology20169:72

https://doi.org/10.1186/s13045-016-0303-0

Received: 9 August 2016

Accepted: 18 August 2016

Published: 23 August 2016

Abstract

We demonstrate the synergistic antitumor effect of oridonin and the PI3K/mTOR inhibitor NVP-BEZ235 on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) both in vitro and in vivo. The underlying mechanism may be multifunctional, involving apoptosis, AKT/mTOR and NF-kB inactivation, and ROS-mediated DNA damage response. Our findings pave the way for a new potential treatment option for non-GCB DLBCL with the combination of oridonin and NVP-BEZ235.

Keywords

Diffuse large B cell lymphomaOridoninNVP-BEZ235ApoptosisPI3K/mTORNF-kB

Findings

Diffuse large B cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin’s lymphoma (NHL) in adults, and it can be distinguished into two major groups, the germinal center B cell (GCB) subtype and the non-germinal center B cell-like (non-GCB) subtype [1, 2]. The non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) presents aggressive clinical courses and poor prognosis [3, 4]. Targeting key pathways may raise the possibility of improving clinical outcomes.

Our previous studies have indicated that oridonin and NVP-BEZ235 have some antitumor effects in DLBCL cells [5, 6]. The aim of this study was to determine whether oridonin combined with NVP-BEZ235 could achieve a more significant antitumor effect on the non-GCB DLBCL, and to further investigate the underlying mechanism. The materials and methods used in this study are detailed in Additional file 1.

Our results demonstrate that oridonin and NVP-BEZ235 exhibit a synergistic effect on non-GCB DLBCL cell lines (OCI-Ly3 and SU-DHL-2), and the co-treatment was more effective on cell proliferation inhibition compared with single-agent therapy (Additional file 2). And then cytotoxic effect of oridonin and NVP-BEZ235 alone or in combination were evaluated in nude mice bearing SU-DHL-2 tumors. Compared with the control group or single-agent group, the co-treatment group exhibited more significant DLBCL cell growth inhibition in terms of tumor size (Fig. 1a) and weight (Fig. 1d) and prolonged the mice survival (Fig. 1b). H&E staining and TUNEL assay showed that co-treatment with oridonin and NVP-BEZ235 obviously increased apoptosis (Fig. 1c, e).
Fig. 1

Oridonin combined with NVP-BEZ235 dramatically inhibited tumor growth and prolonged the survival in a non-GCB DLBCL xenograft mouse model (SU-DHL-2). a, d Mice in each cohort were treated with oridonin (5 mg/kg) and NVP-BEZ235 (20 mg/kg) alone or in combination every other day. Tumor volumes were measured once every 4 days. After 32 days, the mice were sacrificed, and the tumors were removed and weighed. b Overall survival was prolonged by oridonin and NVP-BEZ235 combination therapy compared with the control group and single-agent group (p < 0.005). c HE staining and TUNEL assay was performed to examine the apoptosis in tumor tissues. e Bar graph illustrate the proportion of positive cells showed in TUNEL assay. *p < 0.05, **p <0.01, ***p < 0.001 compared with the control group; # p < 0. 05, ## p < 0.01 compared with single-agent group

To explore the mechanism underlying the synergistic antitumor effect, both cell lines were exposed to 2 μM oridonin and 25 nM NVP-BEZ235 alone or in combination for 24 and 48 h. The results showed that the co-treatment induced higher apoptosis in non-GCB DLBCL cell lines (Fig. 2a, b). Meanwhile, the apoptosis induced by the drug combination was further confirmed by assessment of caspase family and Bcl-2 family protein expression (Additional file 3). However, co-treatment does not further enhance cell-cycle arrest in G0/G1 phase (Additional file 4).
Fig. 2

The mechanism of synergistic antitumor effect of oridonin and NVP-BEZ235 on non-GCB DLBCL. a, b Cell lines were treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) alone or in combination for 24 and 48 h, analyzing apoptosis by Annexin-V/PI staining. c Cell lines were treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) alone or in combination for 48 h. Western blot analysis was performed to identify the expression of total AKT, p-AKT (Ser473), p-AKT (Thr308), mTOR, and p-mTOR. d Western blot for NF-kB, p-NF-kB, IkBα, and p-IkBα. e The expression of γH2AX and H2AX was analyzed by western blotting. f Cell lines were simultaneously treated with oridonin (2 μM) and NVP-BEZ235 (25 nM) for 48 h, and FACS quantitative analysis of DCF-DA was used to detect the expression of ROS. g Pretreatment of co-treatment group cells with NAC (5 mM) and Z-DEVD-FMK (10 μM), respectively, for 48 h, analyzing apoptosis by Annexin-V/PI staining with t test statistic assay. (Mean ± SD, n = 3, *p < 0.05, **p < 0.01 compared with Ori + BEZ group. Z: Z-DEVD-FMK)

To further investigate the mechanism of synergistic drug effects, the expression of AKT/mTOR and NF-kB pathway was assessed by western blotting. The data suggest that the simultaneous inhibition of the PI3K/AKT/mTOR and NF-kB pathways abrogated the key survival signals for non-GCB DLBCL, which might indicate the mechanism for the synergistic pro-apoptotic effect of oridonin and NVP-BEZ235 in combination (Fig. 2c, d). We then found that oridonin and NVP-BEZ235 in combination markedly induced the expression of γH2AX, a marker of DNA damage. Flow cytometry also demonstrated a significant increase in reactive oxygen species (ROS) (Fig. 2e, f). Addition of N-acetyl-l-cysteine (NAC) largely reversed co-treatment-induced apoptosis, while treating the cells with Z-DEVD-FMK (caspase 3 inhibitor) had little effect (Fig. 2g, Additional file 5).

Taken together, our findings demonstrated the synergistic antitumor effect of oridonin combined with NVP-BEZ235 in non-GCB DLBCL cell lines. The potential molecular mechanism might be multifunctional, involving apoptosis, AKT/mTOR and NF-kB inactivation, and ROS-mediated DNA damage response. Moreover, co-treatment was also effective in a non-GCB DLBCL xenograft model. Therefore, our study provides a theoretical basis and preclinical evidence for this novel strategy and suggests that the combination of oridonin and NVP-BEZ235 might have promising therapeutic application in non-GCB DLBCL patients.

Abbreviations

DLBCL: 

Diffuse large B cell lymphoma

ROS: 

Reactive oxygen species

non-GCB: 

Non-germinal center B cell-like

GCB: 

Germinal center B cell

OS: 

Overall survival

PFS: 

Progression free survival

R-CHOP: 

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

NF-kB: 

Nuclear factor kappa B

Ori: 

Oridonin

BEZ: 

NVP-BEZ235

NAC: 

N-acetyl-l-cysteine

Tunel: 

Terminal deoxytransferase-catalyzed DNA nick-end labeling

H&E: 

Hematoxylin and eosin

Declarations

Acknowledgements

This work was partly supported by the National Natural Sciences Foundation of China (81500162) and the Natural Science Foundation of Shanghai (14ZR1425900).

Funding

(1) National Natural Sciences Foundation of China (81500162); and (2) Natural Science Foundation of Shanghai (14ZR1425900).

Availability of data and materials

The data and materials supporting the conclusions of this article is included within the article.

Authors’ contributions

KQ and ZJ performed the experiments. WF and WW analyzed the data. ZL and XL reviewed the data. KQ wrote the paper. ZX and JL designed the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All animal procedures described in this article have been approved by the Animal Care and Use Committee of Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University
(2)
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University
(3)
Department of Laboratory Medicine, Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.View ArticlePubMedGoogle Scholar
  2. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32.View ArticlePubMedGoogle Scholar
  3. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13(5):325–34.View ArticlePubMedGoogle Scholar
  4. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.View ArticlePubMedGoogle Scholar
  5. Xu ZZ, Fu WB, Jin Z, Guo P, Wang WF, Li JM. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma. Leuk Lymphoma. 2016;57(4):888–98.View ArticlePubMedGoogle Scholar
  6. Jin Z, Qing K, Ouyang Y, Liu Z, Wang W, Li X, et al. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. J Exp Clin Cancer Res. 2016;35(1):52.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement